N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study

N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study

Bibliografische gegevens
Hoofdauteurs:	Emberson, J, Armitage, J, Ng, L, Bowman, L, Parish, S, Collins, R, Collaborati, H
Formaat:	Conference item
Gepubliceerd in:	2005

Gelijkaardige items

N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.
door: Emberson, JR, et al.
Gepubliceerd in: (2007)

N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study
door: Emberson, J, et al.
Gepubliceerd in: (2005)

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial
door: Collins, R, et al.
Gepubliceerd in: (2002)

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
door: Heart Protection Study Collaborative Group
Gepubliceerd in: (2002)

MRC/BHF Heart Protection Study - Reply
door: Collins, R, et al.
Gepubliceerd in: (2002)

Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial
door: Mihaylova, B, et al.
Gepubliceerd in: (2005)

Comments on the MRC/BHF Heart Protection Study - Authors' reply
door: Collins, R, et al.
Gepubliceerd in: (2003)

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.
door: Parish, S, et al.
Gepubliceerd in: (2012)

The MRC/BHF Heart Protection Study: preliminary results.
door: Collins, R, et al.
Gepubliceerd in: (2002)

MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS
door: Bulbulia, R, et al.
Gepubliceerd in: (2007)

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
door: Mihaylova, B, et al.
Gepubliceerd in: (2005)

Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.
door: Armitage, J, et al.
Gepubliceerd in: (2009)

MRC/BHF Heart Protection Study.
door: Vaughan, C, et al.
Gepubliceerd in: (2002)

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
door: Bulbulia, R, et al.
Gepubliceerd in: (2011)

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
door: Collins, R, et al.
Gepubliceerd in: (2003)

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
door: Mihaylova, B, et al.
Gepubliceerd in: (2006)

Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials.
door: Armitage, J, et al.
Gepubliceerd in: (2000)

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
door: Collins, R, et al.
Gepubliceerd in: (2004)

Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions
door: Heart Protection Study Collaborative Group
Gepubliceerd in: (2007)

C-reactive protein in the Heart Protection Study Reply
door: Emberson, J, et al.
Gepubliceerd in: (2011)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
door: Hopewell, J, et al.
Gepubliceerd in: (2009)

N-terminal-pro-brain natriuretic peptide, but not brain natriuretic peptide, is increased in patients with severe obesity
door: F. Fernandes, et al.
Gepubliceerd in: (2007-02-01)

The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology
door: R. R. J. van Kimmenade, et al.
Gepubliceerd in: (2006-01-01)

Serum brain natriuretic peptide (BNP) and N-terminal brain natriuretic peptide (NT-proBNP) in heart valve disease
door: J.A. Moolman, et al.
Gepubliceerd in: (2017-04-01)

N‐Terminal Pro Brain, N‐Terminal Pro Atrial Natriuretic Peptides, and Dynamic Cerebral Autoregulation
door: Simin Mahinrad, et al.
Gepubliceerd in: (2020-10-01)

The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393].
door: Group, H
Gepubliceerd in: (2005)

The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]
Gepubliceerd in: (2005-03-01)

Lipoprotein-associated phospholipase A(2) activity and mass in relation to vascular disease and nonvascular mortality
door: Parish, S, et al.
Gepubliceerd in: (2010)

Association of N-Terminal Pro Brain Natriuretic Peptide with Ventricular Ectopy
door: Shazadi Ambreen , Humaira Fayyaz , Azmat Hayyat
Gepubliceerd in: (2021-12-01)

N-Terminal Pro–B-Type Natriuretic Peptide and Incident CKD
door: Takaya Sasaki, et al.
Gepubliceerd in: (2021-04-01)

Artificial Intelligence-Enabled Electrocardiography Detects B-Type Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide
door: Pang-Yen Liu, et al.
Gepubliceerd in: (2023-08-01)

The level of N-terminal pro-brain natriuretic peptide depending on vascular wall condition and bone mass in postmenopausal women
door: I. A. Skripnikova, et al.
Gepubliceerd in: (2020-07-01)

Clinical significance of N-terminal proBrain natriuretic peptide in hypertophic cardiomyopathy
door: Efthimiadis, G, et al.
Gepubliceerd in: (2006)

N-terminal Pro-B-Type Natriuretic Peptide and Malnutrition in Patients on Hemodialysis
door: Jacques Ducros, et al.
Gepubliceerd in: (2020-01-01)

The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology
door: Van Kimmenade, et al.
Gepubliceerd in: (2006-01-01)

Plasma N-terminal pro-brain natriuretic peptide has similar predictive value to brain natriuretic peptide in diagnosis of heart failure in the community
door: Hobbs, R, et al.
Gepubliceerd in: (2000)

Serial measurements of N-terminal pro-brain natriuretic peptide in patients with coronary heart disease.
door: Dhayana Dallmeier, et al.
Gepubliceerd in: (2015-01-01)

B-type and N-terminal pro-B-type natriuretic peptides in heart failure
door: Kurtinecz, M
Gepubliceerd in: (2018)

Significance of N-terminal pro-B-type natriuretic peptide levels in lung cancer
door: Sinem İnan, et al.
Gepubliceerd in: (2025-01-01)

Diagnostic value of N-terminal pro-B-type natriuretic peptide in hemodialysis patients
door: D. S. Sedov, et al.
Gepubliceerd in: (2020-02-01)